跳至主要内容
临床试验/NCT01234441
NCT01234441已完成不适用

Intradialytic Protein Supplementation & Exercise Training in Dialysis Patients.

University of Illinois at Urbana-Champaign4 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2010年12月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
138
试验地点
4
主要终点
Examine the effects of intradialytic oral protein supplementation and exercise training on physical function.

研究概览

简要总结

Chronic kidney disease (CKD) patients receiving hemodialysis treatment (CKD stage 5) suffer from a variety of co-morbid diseases, many of which may be mechanistically linked. Protein malnutrition, muscle catabolism and wasting are especially common, and these lead to reduced muscle strength, declines in physical function, and low levels of physical activity. Physical inactivity exacerbates these functional declines, and also promotes cardiovascular disease (CVD) and bone disorders. This cycle of disease and disability greatly reduces quality of life (QOL) and increases mortality rates in dialysis patients.

Many factors contribute to the development of these co-morbidities. Chronic inflammation is believed to be a cause and a consequence of the protein malnutrition, CVD and bone disorders in dialysis patients. In addition, abnormalities in mineral metabolism resulting from the deficit in kidney function promote the loss of mineral from bone and the deposition of mineral in the vasculature, a process termed vascular calcification (VC). VC is associated with a variety of CVD-related disorders, including arterial stiffness, increases in arterial wall intima-media thickness (IMT), left ventricular hypertrophy (LVH), and declines in cardiac function. As a result of these abnormalities, cardiovascular events are 10 to 30 times greater in dialysis patients than in age- and sex-matched subjects in the general population.

详细描述

Chronic kidney disease (CKD) patients receiving hemodialysis treatment (CKD stage 5) suffer from a variety of co-morbid diseases, many of which may be mechanistically linked. Protein malnutrition, muscle catabolism and wasting are especially common, and these lead to reduced muscle strength, declines in physical function, and low levels of physical activity. Physical inactivity exacerbates these functional declines, and also promotes cardiovascular disease (CVD) and bone disorders. This cycle of disease and disability greatly reduces quality of life (QOL) and increases mortality rates in dialysis patients.

Many factors contribute to the development of these co-morbidities. Chronic inflammation is believed to be a cause and a consequence of the protein malnutrition, CVD and bone disorders in dialysis patients. In addition, abnormalities in mineral metabolism resulting from the deficit in kidney function promote the loss of mineral from bone and the deposition of mineral in the vasculature, a process termed vascular calcification (VC). VC is associated with a variety of CVD-related disorders, including arterial stiffness, increases in arterial wall intima-media thickness (IMT), left ventricular hypertrophy (LVH), and declines in cardiac function. As a result of these abnormalities, cardiovascular events are 10 to 30 times greater in dialysis patients than in age- and sex-matched subjects in the general population.

A variety of pharmacological therapies are commonly used to help prevent or attenuate the progression of CKD co-morbidities; however, morbidity and mortality in this population remain extremely high, indicating that additional therapeutic strategies that may improve the health and QOL in this population are needed. Recently, the National Kidney Foundation recommended that dialysis patients increase their protein intake to 1.2 g/kg/day to help prevent protein malnutrition; however, little is known about the efficacy of this recommendation. Intradialytic (during dialysis) protein supplementation has been shown to increase serum albumin levels11, and also increases amino acid uptake into skeletal muscle, an effect that is potentiated by both resistance and endurance exercise. However, the individual and combined effects of intradialytic protein supplementation and exercise training on lean mass, muscle strength, and physical function is unknown. Furthermore, intradialytic protein supplementation and exercise training improve many risk factors associated with CVD and renal bone disease (e.g., plasma lipids, inflammatory variables), but their effect on functional CVD outcomes (e.g., arterial stiffness, VC, IMT, LVH, myocardial performance) and bone health in dialysis patients is unknown.

The primary objective of the proposed research is to evaluate the efficacy of intradialytic oral protein supplementation, with and without concomitant intradialytic endurance exercise training (cycling), on physical function, CVD risk, and bone health. We will also examine potential mechanisms for these effects, and determine if improvements in these factors lead to improvements in QOL. Hemodialysis patients will be randomized to the following groups for 12 months: 1) usual care/control (CON); 2) intradialytic protein supplementation (PRO); or 3) intradialytic protein supplementation + exercise training (PRO+EX).

Primary Aim #1: Examine the effects of intradialytic oral protein supplementation and exercise training on physical function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must receive hemodialysis treatment at least 3 days per week.
  • Must be ≥ 30 years of age.
  • Must be willing to be randomized to the control or intervention groups.
  • Must be physically able to exercise (e.g., no orthopedic problems that would preclude them from cycling during dialysis).
  • Must receive medical clearance from their primary care physician to participate.
  • Must be on phosphate binders to control calcium levels.

排除标准

  • Persistent hemoglobin levels < 10g/dl.
  • Weight greater than 300 pounds.
  • Currently receiving any form of intradialytic protein supplementation (oral, enteral, or parenteral) or participating in any form of intradialytic exercise training.
  • Chronic obstructive pulmonary disease (COPD) and decompensated chronic heart failure (CHF).
  • On dialysis treatment for < 3 months (or enrollment may be postponed).

研究组 & 干预措施

Control

Sham Comparator

This group of patients will receive a non-nutritive beverage, and no exercise.

干预措施: Control (Dietary Supplement)

Protein

Active Comparator

This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session

干预措施: Protein (Dietary Supplement)

Protein + Exercise

Active Comparator

This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment

干预措施: Protein + Exercise (Behavioral)

结局指标

主要结局

Examine the effects of intradialytic oral protein supplementation and exercise training on physical function.

时间窗: 12 months

Physical function, as assessed by a shuttle walk test, will improve in PRO+EX and PRO, compared to CON, and the magnitude of improvements will be greatest in PRO+EX. In secondary analyses, we also will examine the effects of our interventions on other variables related to physical function, including lean body mass, muscle strength, and activities of daily living (ADL) assessments.

次要结局

  • Examine the effects of intradialytic oral protein supplementation and exercise training on CVD risk.(12 months)
  • Examine the effects of intradialytic oral protein supplementation and exercise training on bone health as determined by bone mineral density (BMD).(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kenneth Wilund

Prinicipal Responsiple Investigator

University of Illinois at Urbana-Champaign

研究点 (4)

Loading locations...

相似试验

Intra Hemodialytic Oral Protein and Exercise (IHOPE) | 临床试验